The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£11,000 tucked away? Here’s how I’d aim to turn that into a passive income worth nearly £17,000 a year!

This Fool wouldn't leave his cash sitting in the bank. Instead, he'd invest in the stock market to start making…

Read more »

Investing Articles

2 cracking dividend shares I’m eyeing for my portfolio

This Fool takes a closer look at two dividend shares he's got on his watchlist. He believes they could make…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

No savings after inflation? I’d use the Warren Buffett method to build wealth

I think this trio of investing principles from billionaire Warren Buffett could be the key to recovering from the UK…

Read more »

Investing Articles

UK REITs: a rare passive income opportunity right now

UK REITs have taken a serious beating over the last two years, and they now could be some of the…

Read more »

Investing Articles

How I’m investing in dividend stocks to aim for £100 weekly passive income

Earning a passive income from dividend stocks isn’t complicated, says Zaven Boyrazian, as he breaks down how he’d target making…

Read more »

Investing Articles

1,043 National Grid shares could make £3,292 a year in passive income!

National Grid shares deliver a high yield that can generate significant passive income, especially if the dividends are used to…

Read more »

Investing Articles

Is the Rolls-Royce share price ready to break through 500p?

Rolls-Royce is part-way through a multi-year transformation programme. Our writer explores if its share price has room to fly.

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

How I’d invest £20k in a Stocks and Shares ISA to target £951,608

There are more than 4,000 ISA millionaires in the UK. Our writer outlines his plan and looks at a top…

Read more »